

Pharmaids Pharmaceuticals Limited

4-4-211/212/11-12, Inderbagh, Hyderabad – 500 095.


Email: mailpharmaids@yahoo.co.in, Website: www.pharmaids.com

STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED 31ST MARCH 2015

PART - I

(Rs. in Lakhs)

	Particulars	QUARTER ENDED			YEAR ENDED	
		31.03.2015	31.12.2014	31.03.2014	31.03.2015	31.03.2014
1	Income from Operations	UN AUDITED			AUDITED	AUDITED
	(a) Net Sales/Income from operations	31.94	50.61	40.44	173.04	140.52
	(b) Other Operating Income	0.00	0.00	0.00	0.00	0.00
	Total Income from Operations	31.94	50.61	40.44	173.04	140.52
2	Expenses					
	a. Consumption of raw materials	0.00	0.00	0.00	0.00	0.00
	b. Purchases of stock-in-trade	10.94	42.39	35.32	104.19	103.94
	c. Increase/decrease in stock in trade and WIP	13.56	(15.00)	(5.43)	(0.50)	(5.52)
	d. Power & Fuel	0.00	0.00	0.00	0.00	0.00
	e. Sales Tax and other Taxes	0.00	0.00	0.00	0.00	0.00
	f. Employees Cost	3.25	5.65	1.81	18.20	9.55
	g. Depreciation	8.67	1.68	2.00	13.71	8.00
	h. Other expenditure	11.76	14.09	45.48	60.31	76.18
	Total	48.18	48.81	79.18	195.91	192.15
	(Any item exceeding 10% of the total expenditure to be shown separately)	0.00	0.00	0.00	0.00	0.00
3	Profit / (Loss) from Operations before other Income, finance costs and Exceptional Items (1-2)	(16.24)	1.80	(38.74)	(22.87)	(51.63)
4	Other Income	0.00	0.04	7.36	12.42	15.84
5	Profit / (Loss) from Ordinary activities before finance costs and exceptional items	-16.24	1.84	-31.38	(10.45)	(35.79)
6	Finance Cost	0.15	0.00	0.30	0.15	0.81
7	Profit / (Loss) from Ordinary activities after finance costs but before exceptional items	(16.39)	1.84	(31.68)	(10.60)	(36.60)
8	Exceptional Items - Expenditure / (Income)	0.00	0.00	0.00	0.00	0.00
9	Profit / (Loss) from Ordinary Activities before tax	(16.39)	1.84	(31.68)	(10.60)	(36.60)
10	Tax expense					
	a) Provision for Taxation	0.00	0.00	0.00	0.00	0.00
	b) Provision for Deferred tax	0.00	0.00	0.00	4.05	1.17
	c) MAT Credit	0.00	0.00	0.00	0.00	0.00
11	Net Profit (+) / Loss (-) from ordinary activities after tax	(16.39)	1.84	(31.68)	(6.55)	(35.43)
12	Extraordinary items (net of tax expense Rs.Nil)	Nil	Nil	Nil	Nil	Nil
13	Net Profit (+)/Loss (-) for the period	(16.39)	1.84	(31.68)	(6.55)	(35.43)
14	Paid-up equity share capital (Face value of the Share is Rs 10/- each)	336.31	336.31	336.31	336.31	336.31
15	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	9.94	9.94	9.94	9.94	9.94
16	Earnings Per Share (before extraordinary items - not					
	a) Basic	(0.48)	0.05	(0.93)	(0.19)	(1.04)
	b) Diluted	(0.48)	0.05	(0.93)	(0.19)	(1.04)
17	Earnings Per Share (after extraordinary items - not annualised)					
	a) Basic	(0.48)	0.05	(0.93)	(0.19)	(1.04)
	b) Diluted	(0.48)	0.05	(0.93)	(0.19)	(1.04)




PART - II						
S.No	Particulars	UN-AUDITED			AUDITED	
		31.03.2015	31.12.2014	31.03.2014	31.03.2015	31.03.2014
A. Particulars of Shareholding						
1	Public shareholding					
	- Number of shares	3,155,886	3,148,711	3,166,405	3,166,405	3,166,405
	- Percentage of shareholding	92.67%	92.46%	92.98%	92.98%	92.98%
2	Promoters and Promoter Group					
	Shareholding					
	a Pledged/Encumbered - No. of Shares	Nil	Nil	Nil	Nil	Nil
	percentage of shares	Nil	Nil	Nil	Nil	Nil
	(as a % of the total shareholding of promoter and promoter group)					
	percentage of shares	Nil	Nil	Nil	Nil	Nil
	(as a % of the total share capital of the Co.)					
	b Non - encumbered					
	Number of shares	249,614	256,789	239,095	239,095	239,095
	percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%
	percentage of shares (as a % of the total sharecapital of the company)	7.33%	7.54%	7.02%	7.02%	7.02%

1. The above Audited of the company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 29th May, 2015.
2. Amount for the quarter ended 31 March 2015 and 31 March 2014 represents the balancing amount between the audited amounts for the financial year and the published year to date amounts up to the third quarter of the current and previous financial year respectively.
3. The company operates in a single segment and the results pertain to a single segment. i.e., drug formulation only.
4. There were no investor complaints pending at the beginning of the quarter and no investor complaint was received and remained pending at the end of the said quarter.
5. Figures for the previous period have been re-grouped or re-arranged wherever considered necessary.

For PHARMAIDS PHARMACEUTICALS LIMITED

Ghansu Jain
Dr. Ghansu Jain
Chairman & Managing Director

PLACE : HYDERABAD
DATE :29.05.2015





Pharmaids Pharmaceuticals Ltd.

4-4-211/212/11-12, Inderbagh, Hyderabad - 500 095.
Email: mailpharmaids@yahoo.co.in Website: www.pharmaids.com
CIN No. L52520TG1989PLC009679

STANDALONE STATEMENT OF ASSETS & LIABILITIES AS ON 31.03.2015

(Rs. In lakhs)

Particulars	As on 31.03.2015	As on 31.03.2014
	Audited	Audited
A		
EQUITY AND LIABILITY		
1 SHARE HOLDERS' FUNDS:		
(a) Share Capital	336.31	336.31
(b) Reserves and Surplus	(164.74)	(154.83)
Sub Total - Shareholders Fund	171.57	181.48
2 Share application money pending allotment	0.00	0.00
3 Minority Interest	0.00	0.00
4 Non-Current Liabilities		
(a) Long term Borrowings	20.66	33.81
(b) Deferred Tax (Net)	6.17	10.23
(c) Other Long term Liabilities	0.00	0.00
(d) Long Term Provisions	0.00	0.00
Sub-Total - Non Current Liabilities	26.83	44.04
5 Current Liabilities		
(a) Short Term Borrowings	9.02	2.18
(b) Trade Payables	40.95	52.77
(c) Other Current Liabilities	3.90	9.25
(d) Short Term Provisions	0.00	0.00
Sub-Total - Current Liabilities	53.87	64.20
TOTAL EQUITY AND LIABILITY	252.27	289.72
B		
ASSETS		
1 Non-Current Assets		
(A) Fixed Asset	46.30	61.88
(b) Non Current Investment	0.00	0.00
(c) Deferred Tax Asset (Net)	0.00	0.00
(d) Long term Loans and Advances	46.87	57.90
(e) Other Non-Current Assets	0.00	0.00
Sub-Total Non-Current Assets	93.17	119.78
2 Current Assets		
(a) Current Investments	0.00	0.00
(b) Inventories	28.98	28.22
(c) Trade Receivables	111.02	125.61
(d) Cash and Cash equivalents	19.10	12.65
(e) Short Term Loans and Advances	0.00	0.00
(f) Other Current Assets	0.00	3.47
Sub-Total Current Assets	159.10	169.94
TOTAL	252.27	289.72

For PHARMAIDS PHARMACEUTICALS LIMITED

Gururaj

Dr. Ghisulal Jain
Chairman & Managing Director



PLACE : HYDERABAD

DATE :29.05.2015



Date : 29/7/15

Annexure VII to Clause 41

Auditor's Report On Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Clause 41 of the Listing Agreement


To
Board of Directors
Pharmaids Pharmaceuticals Limited
Hyderabad

We have audited the quarterly financial results of M/s. Pharmaids Pharmaceuticals Limited for the quarter ended **31st March 2015** and the year to date results for the period **01st April 2014 to 31st March 2015** attached herewith, being submitted by the company pursuant to the requirement of clause 41 of the Listing Agreement except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25, of by the Institute of Chartered Accountants of India Interim Financial Reporting, specified under section 133 of the Companies Act 2013, read with Rule 7 of the Companies (Accounts) Rules 2014 and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

- (i) are presented in accordance with the requirements of clause 41 of the Listing Agreement in this regard; and





RAKESH S JAIN & ASSOCIATES
CHARTERED ACCOUNTANTS

14-6-191, Nagar Khana, Begum Bazar,
HYDERABAD - 500 012. (A.P.) INDIA

E-mail : rsjainassociates@rediffmail.com
Phone : 040-24614481, Fax : 040-24617420
Suresh Kumar Jain (Mob) : +91-9849025612
B. Ramesh Kumar (Mob) : +91-9849025641


Date :

- (ii) give a true and fair view of the net Loss and other financial information for the quarter ended 31st March 2015 as well as the year to date results for the period from 01st April 2014 to 31st March 2015.

Further, we also report that we have, on the basis of the books of account and other records and information and explanations given to us by the management, also verified the number of shares as well as percentage of shareholdings in respect of aggregate amount of public shareholdings, as furnished by the company in terms of clause 35 of the Listing Agreement and found the same to be correct.

For Rakesh S Jain & Associates
Chartered Accountants

B. Ramesh Kumar
B Ramesh Kumar
Partner
M.No. 200304
Firm Regn No. 010129S



Place: Hyderabad
Date : 29.05.2015